[1] |
Jiang J, Shen Y, Wu C, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients[J]. World J Gastroenterol 2010 ,16(48): 6155-6162.
|
[1] |
Jiang J, Shen Y, Wu C, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients[J]. World J Gastroenterol 2010 ,16(48): 6155-6162.
|
[2] |
Wu C, Jiang J, Shi L,et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer[J].Anticancer Res, 2008,28: 3997-4002.
|
[2] |
Wu C, Jiang J, Shi L,et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer[J].Anticancer Res, 2008,28: 3997-4002.
|
[3] |
Hoffman D M,Gitlitz B J,Belldegrun A,et al.Adoptive cellular therapy[J].Semin Oncol,2000,27(2):221-233.
|
[4] |
Yeon Jin Kim, Jaeseung Lim, Jong Soon Kang,et al.Adoptive Immunotherapy of Human Gastric Cancer with Ex Vivo Expanded T Cells[J].Arch Pharm Res,2010, 33(11):1789-1795.
|
[3] |
Hoffman D M,Gitlitz B J,Belldegrun A,et al.Adoptive cellular therapy[J].Semin Oncol,2000,27(2):221-233.
|
[5] |
Takayama T, Sekine T, Makuuchi M,et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. Lancet,2000,356,802-807.
|
[4] |
Yeon Jin Kim, Jaeseung Lim, Jong Soon Kang,et al.Adoptive Immunotherapy of Human Gastric Cancer with Ex Vivo Expanded T Cells[J].Arch Pharm Res,2010, 33(11):1789-1795.
|
[6] |
Schmidt-Wolf I G,Lefterova P,Mehta B A,et al.Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells[J].Exp Hematol,1993,21:1673-1679.
|
[7] |
Schrmitz M,Zhao S,Deuse Y,et al.Tumorcidal potential of native blood dendritic cells:direct tumor cell killing and activation of NK cell-mediated cytotoxicity[J].J Immunol,2005,174(7):4127-4134.
|
[5] |
Takayama T, Sekine T, Makuuchi M,et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. Lancet,2000,356,802-807.
|
[8] |
Bela A Mehta,Schmidt-Wolf IGH,Weissman I L,et al.Two pathways of exocytosis of cytoplasmic granule cotents and target cell killing by cytokine-iuduced CD3+CD56+killer cells[J].Blood,1995,86:3493-3499.
|
[9] |
Brinkmann O A, Bruns F, Gosheger G, et al. Treatment of bone metastases and local recurrence from renal cell carcinoma with immuno chemotherapy and radiation[J]. World J Urol,2005,23(3):185-190.
|
[6] |
Schmidt-Wolf I G,Lefterova P,Mehta B A,et al.Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells[J].Exp Hematol,1993,21:1673-1679.
|
[10] |
Verneris M R, Kornacker M, Mailander V, et al. Resistance ofex vi-vo expanded CD3+ CD56+T cells to Fas-mediated apoptosis[ J]. Cancer Immunol Immunother, 2000, 49 (6):335-345.
|
[7] |
Schrmitz M,Zhao S,Deuse Y,et al.Tumorcidal potential of native blood dendritic cells:direct tumor cell killing and activation of NK cell-mediated cytotoxicity[J].J Immunol,2005,174(7):4127-4134.
|
[11] |
孙 抒,李雪梅,王建光,等.CIK细胞对MGC-803胃癌细胞株抗增殖及诱导凋亡作用的研究[J].中国免疫学杂志,2004,20(12):831-837.
|
[8] |
Bela A Mehta,Schmidt-Wolf IGH,Weissman I L,et al.Two pathways of exocytosis of cytoplasmic granule cotents and target cell killing by cytokine-iuduced CD3+CD56+killer cells[J].Blood,1995,86:3493-3499.
|
[12] |
Parkin D M,Bray F,Ferlay J,et al.Global cancer statistics,2002[J]. CA Cancer J Clin,2005,55(2):74-108.
|
[9] |
Brinkmann O A, Bruns F, Gosheger G, et al. Treatment of bone metastases and local recurrence from renal cell carcinoma with immuno chemotherapy and radiation[J]. World J Urol,2005,23(3):185-190.
|
[13] |
Chen L, Tian H, Chen J, et al.Surgical management of gastric stump cancer: a report of 37cases[J]. J Zhejiang Univ Sci B, 2005,6:38-42.
|
[10] |
Verneris M R, Kornacker M, Mailander V, et al. Resistance ofex vi-vo expanded CD3+ CD56+T cells to Fas-mediated apoptosis[ J]. Cancer Immunol Immunother, 2000, 49 (6):335-345.
|
[11] |
孙 抒,李雪梅,王建光,等.CIK细胞对MGC-803胃癌细胞株抗增殖及诱导凋亡作用的研究[J].中国免疫学杂志,2004,20(12):831-837.
|
[14] |
Lin W L, Li D G, Chen Q, et al. Clinical and experimental study of oxaliplatin in treating human gastric carcinoma[J].World J Gastroenterol, 2004,10: 2911-2915.
|
[12] |
Parkin D M,Bray F,Ferlay J,et al.Global cancer statistics,2002[J]. CA Cancer J Clin,2005,55(2):74-108.
|
[15] |
Schmidt-Wolf IGH, Negrin R S, Kiem H, et al.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity [J]. J Exp Med,1991,174:139-149.
|
[13] |
Chen L, Tian H, Chen J, et al.Surgical management of gastric stump cancer: a report of 37cases[J]. J Zhejiang Univ Sci B, 2005,6:38-42.
|
[16] |
Yamaguchi K, Shimamura T, Hyodo I, et al.Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer[J]. Br J Cancer,2006,94:1803-1808.
|
[14] |
Lin W L, Li D G, Chen Q, et al. Clinical and experimental study of oxaliplatin in treating human gastric carcinoma[J].World J Gastroenterol, 2004,10: 2911-2915.
|
[17] |
Margolin K A, Negrin R S, Wong K K,et al. Cellular immunotherapy and autologous transplantation for hematologic malignancy[J]. Immunol Rev,1997,157: 231-240.
|
[18] |
樊永丽,赵 华,于津浦,等. 胃癌患者术后化疗联合CIK免疫治疗的临床疗效[J].中国肿瘤生物治疗杂志,2012,19(2):168-174.
|
[15] |
Schmidt-Wolf IGH, Negrin R S, Kiem H, et al.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity [J]. J Exp Med,1991,174:139-149.
|
[19] |
Kim Y J,Lim J,Kang J S,et al. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells [J].Arch Pharm Res,2010,33( 11) : 1789-1795.
|
[16] |
Yamaguchi K, Shimamura T, Hyodo I, et al.Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer[J]. Br J Cancer,2006,94:1803-1808.
|
[17] |
Margolin K A, Negrin R S, Wong K K,et al. Cellular immunotherapy and autologous transplantation for hematologic malignancy[J]. Immunol Rev,1997,157: 231-240.
|
[18] |
樊永丽,赵 华,于津浦,等. 胃癌患者术后化疗联合CIK免疫治疗的临床疗效[J].中国肿瘤生物治疗杂志,2012,19(2):168-174.
|
[20] |
杨 光,王 彬,何志杰,等.自体CIK细胞治疗晚期恶性肿瘤的临床研究[J].南京医科大学学报﹙自然科学版﹚,2009,29(12):1744-1747.
|
[21] |
蒋敬庭,吴昌平,Ning Xu,等.CIK细胞治疗老年人中晚期胃癌的副反应分析[J].肿瘤,2006,26(10):950-952.
|
[19] |
Kim Y J,Lim J,Kang J S,et al. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells [J].Arch Pharm Res,2010,33( 11) : 1789-1795.
|
[22] |
Brinkmann O A,Bruns F,Gosheger G,et al.Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation[J].World J Urol,2005,23(3):185-190.
|
[23] |
Jiang J, Xu N, Wu C, et al.Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells[J]. AnticancerRes, 2006, 26: 2237-2242.
|
[24] |
张 彤,任国平,张 蕊.紫杉醇、奥沙利铂、氟尿嘧啶方案联合自体CIK细胞输注治疗Ⅳ期胃癌的疗效与安全性研究[J].中国临床实践,2012,15(7):2418-2410.
|
[20] |
杨 光,王 彬,何志杰,等.自体CIK细胞治疗晚期恶性肿瘤的临床研究[J].南京医科大学学报﹙自然科学版﹚,2009,29(12):1744-1747.
|
[21] |
蒋敬庭,吴昌平,Ning Xu,等.CIK细胞治疗老年人中晚期胃癌的副反应分析[J].肿瘤,2006,26(10):950-952.
|
[25] |
Thome S H,Negrin R S,Contag C H.Synergistic antitumor effects of immune cell—viral biotherapy[J].Science,2006,3(1l):17802-17841.
|
[22] |
Brinkmann O A,Bruns F,Gosheger G,et al.Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation[J].World J Urol,2005,23(3):185-190.
|
[23] |
Jiang J, Xu N, Wu C, et al.Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells[J]. AnticancerRes, 2006, 26: 2237-2242.
|
[26] |
Liu K,Caldwell S A,Greenetlch K M,et al.CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape[J]. J Immunol,2006,176(6):3374-3382.
|
[24] |
张 彤,任国平,张 蕊.紫杉醇、奥沙利铂、氟尿嘧啶方案联合自体CIK细胞输注治疗Ⅳ期胃癌的疗效与安全性研究[J].中国临床实践,2012,15(7):2418-2410.
|
[27] |
Ramakrishnan R, As sudaniD, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility toCTL-mediated killing during cancer immunotherapy in mice [ J]. J Clin Invest, 2010,120(4):1111-1124.
|
[25] |
Thome S H,Negrin R S,Contag C H.Synergistic antitumor effects of immune cell—viral biotherapy[J].Science,2006,3(1l):17802-17841.
|
[28] |
李 辉,毛伟征,安 岗,等.细胞因子诱导杀伤细胞杀伤胃癌的特异性与非特异性研究[J].中华实验外科杂志,2012,27(4):428-430.
|
[26] |
Liu K,Caldwell S A,Greenetlch K M,et al.CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape[J]. J Immunol,2006,176(6):3374-3382.
|
[29] |
Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy[J]. Oncologist, 2002, 7 Suppl 4: 2-8.
|
[30] |
张 林,侯艳红,段云卉.EGFR单抗联合CIK细胞治疗胃癌的实验研究[J].胃肠病学,2010,15(11):657-660.
|
[27] |
Ramakrishnan R, As sudaniD, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility toCTL-mediated killing during cancer immunotherapy in mice [ J]. J Clin Invest, 2010,120(4):1111-1124.
|
[28] |
李 辉,毛伟征,安 岗,等.细胞因子诱导杀伤细胞杀伤胃癌的特异性与非特异性研究[J].中华实验外科杂志,2012,27(4):428-430.
|
[29] |
Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy[J]. Oncologist, 2002, 7 Suppl 4: 2-8.
|
[30] |
张 林,侯艳红,段云卉.EGFR单抗联合CIK细胞治疗胃癌的实验研究[J].胃肠病学,2010,15(11):657-660.
|
|
|